SAPHNELO®

SAPHNELO® Performance Benefits for Clinical Use

SAPHNELO® delivers proven improvements in key lupus outcomes. Patients receiving SAPHNELO® experienced better disease control, reduced steroid use, and fewer flares compared to placebo. It allows for more aggressive tapering of corticosteroids without compromising disease management.

• BICLA response at 52 weeks: 47.1%–47.8% (vs. 30.2%–31.5% placebo)

• SRI-4 response at 52 weeks: Up to 55.5% with SAPHNELO®

• Steroid tapering success (≤7.5 mg/day): 51.5% with SAPHNELO® vs. 30.2% placebo

• Flare reduction (annualized flare rate): 0.43 with SAPHNELO® vs. 0.64 placebo

• Discontinuation due to adverse events: Lower than placebo (4.1% vs. 5.2%)

Ideal SAPHNELO® Use Cases and Patient Profiles

Best suited for adults with persistent lupus symptoms despite standard therapy. Helps reduce steroid burden while maintaining control over disease activity. Should not be used in pediatric patients or those with major organ involvement.

• Target patients:

  • Adults with active, autoantibody-positive SLE

  • Patients unable to taper off corticosteroids

  • Individuals with frequent flares despite standard therapy

• Exclusions:

  • <18 years old

  • Severe lupus nephritis

  • Central nervous system lupus

• Use as: Add-on to corticosteroids, antimalarials, and/or immunosuppressives

SAPHNELO® Core Ingredients and Their Roles

Formulated for IV use with a focus on stability and safety. No preservatives included. Active and non-active components support solubility, isotonicity, and protein structure.

• Active: Anifrolumab 150 mg/mL

• Formulation: 300 mg per 2.0 mL vial

• Excipients:

  • Trehalose dihydrate – stabilizer

  • L-Histidine / L-Histidine hydrochloride monohydrate – buffer

  • L-Lysine hydrochloride – tonicity agent

  • Polysorbate 80 – surfactant

  • Water for injection – diluent

• No preservatives, antimicrobials, or added antibiotics

SAPHNELO® Injection Techniques and Application Guide

Delivered as a slow IV infusion in clinical settings. Preparation and administration follow a clear protocol to ensure safety and performance.

• Dose: 300 mg via IV every 4 weeks

• Infusion time: 30 minutes

• Dilution:

  • Withdraw 2.0 mL from 50–100 mL normal saline

  • Add 2.0 mL SAPHNELO® from vial

  • Gently invert to mix (do not shake)

• Administration:

  • Use 0.2 to 15 μm low-protein-binding in-line filter

  • Flush with 25 mL normal saline post-infusion

• Caution: Do not mix with other medications or reuse vials

SAPHNELO® Storage, Shelf Life, and Handling

Maintaining cold-chain integrity is critical. Diluted solutions have specific usage windows based on temperature conditions.

• Unopened vials:

  • Store at 2°C to 8°C

  • Do not freeze

  • Protect from light

• Post-dilution:

  • 15°C–25°C: Stable for 4 hours

  • 2°C–8°C: Stable for 24 hours

  • Must reach room temperature before administration

• Shelf life: Check expiry on packaging; no preservatives added

SAPHNELO® Side Effects: What to Monitor

Most patients tolerate SAPHNELO® well. Main safety concerns include infection risk and infusion-related events. Herpes zoster occurs more frequently than with placebo.

• Common (≥5%):

  • Nasopharyngitis: 16.3%

  • Upper respiratory tract infection: 15.5%

  • Herpes zoster: 6.1%

  • Infusion-related reactions: 9.4%

• Serious infections: 4.8% vs. 5.6% (placebo)

• Malignancies (excluding non-melanoma skin cancer): 0.7%

• Hypersensitivity reactions: 0.6%

• Discontinuation due to AEs: Lower with SAPHNELO® than placebo

Key Practitioner Questions About SAPHNELO® Answered

Can it be used in children or teens?
No. SAPHNELO® is not authorized for patients under 18.

Is it safe during pregnancy or breastfeeding?
Not recommended. Anifrolumab crosses the placenta and is present in breast milk in animals.

Can patients receive vaccines while on therapy?
Live or attenuated vaccines are contraindicated. Consider timing vaccinations before therapy.

Can it be combined with other biologics?
No. Safety and efficacy of SAPHNELO® with other biologics have not been evaluated.

What if a dose is missed?
Administer missed dose as soon as possible. Maintain a minimum 14-day interval between infusions.

How to Order SAPHNELO® for Your Practice

SAPHNELO® is available in a single-use 300 mg/2 mL vial for hospital or infusion clinic use. It must be stored in temperature-controlled environments and administered by professionals trained in IV therapy.

• Format: 300 mg (150 mg/mL) in 2 mL single-use vial

• Ordering channel: Licensed medical distributors only

• Requires: Cold-chain shipping and secure clinic-based handling

• Not for: Self-injection or retail pharmacy use

Why Order SAPHNELO® forYour Practice

For busy professionals managing complex lupus cases, SAPHNELO® delivers proven disease control, steroid-sparing outcomes, and strong patient adherence with monthly dosing. Backed by clinical trial data, it offers real results in a targeted population.

Use SAPHNELO® to support long-term control of moderate to severe SLE in patients not fully managed by standard therapies.

• Improves composite disease response

• Reduces steroid reliance

• Lowers flare frequency

• Streamlines patient management with monthly IV administration

Consider SAPHNELO® a high-performance addition to your clinic’s SLE treatment options. Doctor Medica can help you order SAPHNELO® online for your practice.